Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Adjuvant treatment of operable node-positive Breast Cancer.
Induction chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Colorectal, Pancreatic, Breast, Non-Small Cell Lung Cancer, Myelodysplastic Syndromes (MDS), and Acute/Chronic Leukemias.
Advanced solid tumors and hematologic malignancies with matching genomic alterations.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
BRAF V600E/K mutation-positive Melanoma, Non-Small Cell Lung Cancer, Anaplastic Thyroid Cancer, and Colorectal Cancer.
Approved for use in oncology care according to FDA-approved indications.
Adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations; first-line treatment for metastatic EGFR-mutated NSCLC; and EGFR T790M mutation-positive metastatic NSCLC.
Deleterious BRCA-mutated or HRD-positive Ovarian, Breast, Pancreatic, and Prostate Cancers.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.